TapewireFind a company

person · Reporting owner

Stanker James H

Disclosed activity across 2 companies

Tapewire entity
88534
SEC CIK
0001681718

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
GSE SYSTEMS INCGVP · Entity 87144DirectorJune 11, 2019June 12, 2019
Processa Pharmaceuticals, Inc.PCSA · Entity 8210Chief Financial OfficerApril 05, 2024August 02, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

GSE SYSTEMS INC

Report date June 11, 2019 · Filed June 12, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect48,118 Reported balance After 2019-06-11 transaction · row 1
1 source row

Row 1 · 2019-06-11 · Grant · Acquired 25,316 · Balance 48,118

F1: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders.

F2: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders.

F2: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer.

Processa Pharmaceuticals, Inc.

Report date April 05, 2024 · Filed August 02, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect6,482 Ending reported balance After 2024-07-10 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2024-04-05 · Exercise / conversion · Acquired 1,675 · Balance 6,638

F1: Distribution of vested restricted shares.

Row 2 · 2024-04-05 · Tax withholding · Disposed 518 · Balance 6,120

Row 3 · 2024-07-10 · Exercise / conversion · Acquired 644 · Balance 6,764

F1: Distribution of vested restricted shares.

Row 4 · 2024-07-10 · Tax withholding · Disposed 282 · Balance 6,482

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct26,470 Reported balance After 2024-06-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2024-06-28 · Grant · Acquired 3,077 · Balance 26,470

F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct28,777 Reported balance After 2024-06-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2024-06-28 · Grant · Acquired 2,307 · Balance 28,777

F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct29,162 Reported balance After 2024-06-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2024-06-28 · Grant · Acquired 385 · Balance 29,162

F4: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct29,547 Reported balance After 2024-06-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2024-06-28 · Grant · Acquired 385 · Balance 29,547

F4: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Filing footnotes · ownership attribution and instrument terms

F1: Distribution of vested restricted shares.

F2: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

F3: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

F4: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
July 10, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 282 $1.71 $482.22
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 4

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,482

Read SEC document
July 10, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 644 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 3

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,764

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 385 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · derivative · entry 8

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,547

Underlying: Common Stock · 385 shares

Expires not disclosed

F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 385 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · derivative · entry 7

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,162

Underlying: Common Stock · 385 shares

Expires not disclosed

F4 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

F4 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 2,307 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · derivative · entry 6

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,777

Underlying: Common Stock · 2,307 shares

Expires not disclosed

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.

Read SEC document
June 28, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 3,077 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · derivative · entry 5

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,470

Underlying: Common Stock · 3,077 shares

Expires not disclosed

F2 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

F2 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on January 1, 2025.

Read SEC document
April 05, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 518 $2.79 $1,445.22
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 2

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,120

Read SEC document
April 05, 2024 Filed Aug 2, 2024 17:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 1,675 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-001613 · form4.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 16:57 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionRestricted Stock Units · Derivative 1,675 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0000897069-24-000923 · form4.xml · derivative · entry 3

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,037

Underlying: Common Stock · 1,675 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Distribution of vested restricted shares.

F1 · derivative.expiration_date: Distribution of vested restricted shares.

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 16:57 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 518 $2.79 $1,445.22
Disclosure

SEC source: 0000897069-24-000923 · form4.xml · nonDerivative · entry 2

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,120

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
January 01, 2024 Filed Apr 12, 2024 16:57 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 1,675 Not disclosed Not disclosed
Disclosure

SEC source: 0000897069-24-000923 · form4.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,638

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Distribution of vested restricted shares.

F2 · balance_after: Effective on January 22, 2024, Processa Pharmaceuticals, Inc. effected a 20 to 1 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

Read SEC document
October 12, 2023 Filed Oct 12, 2023 17:58 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 15,000 $0.33 $4,950.00
Disclosure

SEC source: 0000897069-23-001464 · form4.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,250

Read SEC document
October 10, 2023 Filed Oct 10, 2023 16:51 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 22,500 $0.24 $5,400.00
Disclosure

SEC source: 0000897069-23-001436 · form4.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,250

Read SEC document
February 09, 2023 Filed Feb 10, 2023 17:20 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 12,500 $0.80 $10,000.00
Disclosure

SEC source: 0001567619-23-002403 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,750

Read SEC document
January 01, 2023 Filed Jan 4, 2023 17:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 96,150 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000324 · doc1.xml · derivative · entry 3

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 518,431

Underlying: Common Stock · 96,150 shares

Expires not disclosed

F3 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

F3 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the Issuers common stock, following its vesting of one-third on 01/01/24; 01/01/25 and 01/01/26, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 17:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 69,667 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000324 · doc1.xml · derivative · entry 2

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 422,281

Underlying: Common Stock · 69,667 shares

Expires not disclosed

F2 · derivative.exercise_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

F2 · derivative.expiration_date: Each restricted stock units represents a contingent right to receive one share of the lssuers common stock, following its vesting on 01/01/24, upon the earlier of termination of employment; the third anniversary of the award date; a change in control, or the reporting persons death.

Read SEC document
December 31, 2022 Filed Jan 4, 2023 17:42 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 12,951 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-23-000324 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 352,614

Underlying: Common Stock · 12,951 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units vest on date grant.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death. These restricted stock units vest on date grant.

Read SEC document
September 30, 2022 Filed Oct 5, 2022 16:40 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 12,950 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-018275 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 339,663

Underlying: Common Stock · 12,950 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2 · balance_after: Previous filing inadvertently underreported derivative securities beneficially owned by the reporting person.

Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:28 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Tax withholdingCommon Stock 2,462 $3.17 $7,804.54
Disclosure

SEC source: 0001567619-22-015307 · doc1.xml · nonDerivative · entry 2

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,250

Read SEC document
August 05, 2022 Filed Aug 9, 2022 16:28 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 Exercise / conversionCommon Stock 7,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-22-015307 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,712

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Vesting of time-based restricted shares.

Read SEC document
June 30, 2022 Filed Jul 5, 2022 17:35 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 23,947 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-013682 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,713

Underlying: Common Stock · 23,947 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
June 30, 2022 Filed Oct 3, 2022 16:51 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 23,947 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-018057 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 326,713

Underlying: Common Stock · 23,947 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
April 01, 2022 Filed Apr 11, 2022 17:54 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 247,841 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-008365 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 302,766

Underlying: Common Stock · 247,841 shares

Expires not disclosed

F1 · derivative.exercise_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.

F1 · derivative.expiration_date: Restricted Stock Units (RSUs) vest upon achievement of certain performance goals. The grant of 136,632 RSUs are subject to shareholder approval of the Issuer's 2019 Omnibus Incentive Plan (the "Plan") to increase the authorized shares under the Plan.

F2 · balance_after: The previous filing understated this number. This new total accurately reflects the cumulative total of Restricted Stock Units for the reporting person.

Read SEC document
March 31, 2022 Filed Apr 4, 2022 17:46 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 10,715 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-007982 · doc1.xml · derivative · entry 2

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,781

Underlying: Common Stock · 10,715 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
December 31, 2021 Filed Jan 4, 2022 17:27 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,722 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000294 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,722

Underlying: Common Stock · 6,722 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
December 31, 2021 Filed Jan 6, 2022 17:21 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,722 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000766 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,780

Underlying: Common Stock · 6,722 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance.

Read SEC document
November 01, 2021 Filed Apr 4, 2022 17:46 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 4,286 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-007982 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,066

Underlying: Common Stock · 4,286 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
September 30, 2021 Filed Oct 4, 2021 16:38 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-017827 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,024

Underlying: Common Stock · 6,024 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
September 30, 2021 Filed Jan 6, 2022 16:07 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 6,024 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-22-000724 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,058

Underlying: Common Stock · 6,024 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F2 · balance_after: This Amendment is being filed to correct the balance in Box 9 - this should have reflected a cumulative balance.

Read SEC document
August 05, 2021 Filed Aug 9, 2021 16:38 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantCommon Stock 7,601 Not disclosed Not disclosed
Disclosure

SEC source: 0001567619-21-014749 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,111

F1 · price: Vesting of time-based restricted shares.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 16:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 1,907 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013183 · doc1.xml · derivative · entry 3

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,034

Underlying: Common Stock · 10,034 shares

Expires not disclosed

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 16:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 12,858 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013183 · doc1.xml · derivative · entry 2

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,858

Underlying: Common Stock · 12,858 shares

Expires not disclosed

F2 · derivative.exercise_date: The Restricted Stock Units vest upon achievement of certain performance goals.

F2 · derivative.expiration_date: The Restricted Stock Units vest upon achievement of certain performance goals.

Read SEC document
July 08, 2021 Filed Jul 9, 2021 16:31 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 8,572 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-013183 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,572

Underlying: Common Stock · 8,572 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units vest in two equal installments beginning July 1, 2022.

F1 · derivative.expiration_date: The restricted stock units vest in two equal installments beginning July 1, 2022.

Read SEC document
June 21, 2021 Filed Jun 22, 2021 17:09 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 1,000 $6.81 $6,810.00
Disclosure

SEC source: 0001567619-21-012484 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,510

F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.72 to $6.89, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Read SEC document
June 08, 2021 Filed Jun 10, 2021 17:06 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 GrantRestricted Stock Units · Derivative 8,127 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001567619-21-011980 · doc1.xml · derivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,127

Underlying: Common Stock · 8,127 shares

Expires not disclosed

F1 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

F1 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock upon the earliest of: termination of employment; the third anniversary of the award date; a change of control; or the reporting person's death.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 17:33 UTC Amendment Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 6,000 $4.00 $24,000.00
Disclosure

SEC source: 0001567619-20-017592 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,248

F1 · price: This amended Form 4 is being filed to correct the purchase price for the reported transaction.

Read SEC document
October 01, 2020 Filed Oct 5, 2020 16:43 UTC Processa Pharmaceuticals, Inc. PCSA · Entity 8210 PurchaseCommon Stock 6,000 $2.10 $12,600.00
Disclosure

SEC source: 0001567619-20-017574 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,248

Read SEC document
June 11, 2019 Filed Jun 12, 2019 16:23 UTC GSE SYSTEMS INC GVP · Entity 87144 GrantCommon Stock 25,316 $0.00 $0.00
Disclosure

SEC source: 0001567619-19-013279 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,118

F1 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 11, 2020 or the date of the Issuer's 2020 Annual Meeting of Stockholders.

F2 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer.

Read SEC document
June 12, 2018 Filed Jun 13, 2018 17:13 UTC GSE SYSTEMS INC GVP · Entity 87144 GrantCommon Stock 7,911 $0.00 $0.00
Disclosure

SEC source: 0001140361-18-028441 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,802

F1 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 12, 2019 or the date of the Issuer's 2019 Annual Meeting of Stockholders.

F2 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer.

Read SEC document
June 12, 2017 Filed Jun 14, 2017 16:21 UTC GSE SYSTEMS INC GVP · Entity 87144 GrantCommon Stock 7,352 $0.00 $0.00
Disclosure

SEC source: 0001140361-17-024983 · doc1.xml · nonDerivative · entry 2

Stanker James H · CIK 0001681718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,891

F2 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 7, 2018 or the date of the Issuer's 2018 Annual Meeting of Stockholders.

F3 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer.

Read SEC document
June 12, 2017 Filed Jun 14, 2017 16:21 UTC GSE SYSTEMS INC GVP · Entity 87144 GrantCommon Stock 1,923 $0.00 $0.00
Disclosure

SEC source: 0001140361-17-024983 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,539

F1 · shares: Shares of Common Stock granted to Mr. Stanker on June 12, 2017, in partial compensation for the Mr. Stanker's service as a member of the Issuer's Board of Directors between March 1, 2017 and June 12, 2017.

F1 · price: Shares of Common Stock granted to Mr. Stanker on June 12, 2017, in partial compensation for the Mr. Stanker's service as a member of the Issuer's Board of Directors between March 1, 2017 and June 12, 2017.

Read SEC document
December 08, 2016 Filed Dec 12, 2016 17:07 UTC GSE SYSTEMS INC GVP · Entity 87144 GrantCommon Stock 5,616 $0.00 $0.00
Disclosure

SEC source: 0001140361-16-089399 · doc1.xml · nonDerivative · entry 1

Stanker James H · CIK 0001681718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,616

F1 · shares: These shares of common stock represent restricted share units granted pursuant to a Restricted Share Unit Agreement between Mr. Stanker and the Issuer and are subject to forfeiture. The restricted share units awarded will vest at the earlier of June 7, 2017 or the date of the Issuer's 2017 Annual Meeting of Stockholders.

F2 · price: These restricted share units were granted to Mr. Stanker for his service as a member of the Board of Directors of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.